Ovarian Adnexal Mass Assessment Score Test System
Main Filters
Ovarian Adnexal Mass Assessment Score Test System
| Abbott GmbH | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 03R7521 | 0 | - | ||
| ABBOTT LABORATORIES | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 06P3021 | 0 | - | ||
| Aspira Women's Health Inc. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 3.0.3.006 | 0 | - | ||
| 4.0.0 | 0 | - | ||
| Fujirebio Diagnostics, Inc. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 404-10US | 0 | - | ||
| CL0004 | 0 | - | ||
| Roche Diagnostics GmbH | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 07113358001 | 0 | - | ||
7 Results
Results Per Page
- 50
- 100
- 250
Catalog #
Available
Starting At
Name
Company Name
Description
0
-
OVA1
Aspira Women's Health Inc.
Ova1® is a qualitative serum test that combines the results of five immunoassays into a single numerical result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. Ova1® is an aid to further assess the likelihood that malignancy is present when the physician’s independent clinical and radiological evaluation does not indicate malignancy. The test is not intended as a screening or stand-alone diagnostic assay.
0
-
Overa
Aspira Women's Health Inc.
The Overa® test is a qualitative serum test that combines the results of five immunoassays into a single numeric result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The Overa® test is intended to aid in assessing whether a woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy as part of the preoperative evaluation. The Overa® test must be interpreted in conjunction with an independent clinical and imaging evaluation. The test is not intended as a screening or stand-alone diagnostic assay.